论文部分内容阅读
目的:研究哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)信号通路蛋白在人卵巢上皮性癌中的表达及其临床意义。方法:选取武汉同济医院妇产科2005～2008间手术切除并经病理证实的人卵巢上皮性癌63例,其中Ⅰ级12例、Ⅱ级15例、Ⅲ级23例、Ⅳ级13例,应用免疫组织化学法检测卵巢上皮性癌组织中mTOR信号通路关键蛋白pm-TOR、pAKT的表达,分析其与卵巢癌患者临床病理特征的关系。结果:pmTOR在各级卵巢上皮性癌中的阳性率分别为:Ⅰ级41.7%(5/12)、Ⅱ级53.3%(8/15)、Ⅲ级65.2%(15/23)、Ⅳ级69.2%(9/13),pAKT在各级卵巢上皮性癌中的阳性率分别为:Ⅰ级33.3%(5/12)、Ⅱ级40.0%(6/15)、Ⅲ级52.2%(12/23)、Ⅳ级53.8%(7/13);各阳性表达率间无统计学差异(P>0.05),但其表达水平均随着卵巢上皮性癌病理级别的增高而升高,而与病理类型无关。结论:mTOR信号通路蛋白在卵巢上皮性癌的发生发展中起重要的作用,可能是卵巢癌治疗的潜在靶点。
Objective: To study the expression of mammalian target of rapamycin (mTOR) signaling pathway in human epithelial ovarian cancer and its clinical significance. Methods: Totally 63 cases of human ovarian epithelial carcinoma surgically removed and confirmed by pathology were selected from Department of Obstetrics and Gynecology, Tongji Hospital, Wuhan from 2005 to 2008. Among them, 12 cases were grade Ⅰ, 15 cases were Ⅱ, 23 cases were Ⅲ and 13 cases were Ⅳ. Immunohistochemistry was used to detect the expression of pm-TOR and pAKT, the key proteins of mTOR signaling pathway in epithelial ovarian cancer, and their relationship with the clinicopathological features of ovarian cancer patients. Results: The positive rates of pmTOR in epithelial ovarian cancer at all stages were 41.7% (Ⅰ / 2), 53.3% (8/15), 65.2% (15/23) and 69.2 % (9/13). The positive rates of pAKT in epithelial ovarian cancer at all stages were 33.3% (5/12), 40.0% (6/15), 52.2% (12/23) ), Grade Ⅳ 53.8% (7/13). There was no significant difference between the positive expression rates (P> 0.05), but the expression levels increased with the pathological grade of epithelial ovarian cancer, Nothing to do Conclusion: mTOR signaling pathway protein plays an important role in the occurrence and development of epithelial ovarian cancer and may be a potential target for the treatment of ovarian cancer.